Revumenib Citrate Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Revumenib is an oral small molecule menin inhibitor that prevents the interaction between menin and aberrant KMT2A. It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations. Revumenib Citrate is a common salt of Revumenib.

Revumenib Citrate Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Revumenib Citrate Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Chongqing jooe co., ltd	+undefined86-15223382610	info@jooe.com	China	15976	58
Changzhou Xuanming Pharmaceutical Technology Co., Ltd.	+86-519-85525359 +86-15995072465	sales@xuanmingchem.com	China	912	58
Dideu Industries Group Limited	+86-29-89586680 +86-15129568250	1026@dideu.com	China	28760	58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.	+86-18600796368	sales@sjar-tech.com	China	529	58
JINAN SHENGQI PHARMACEUTICAL CO., LTD	0531-88892685 15069007290;18660160628	15069007290@163.com	China	168	58
Aktin Chemicals, Inc.	028-85159085	info@aktinchem.com	China	2017	58
Hunan ravel Biotechnology Co.,Ltd	18502762003	435918333@qq.com	China	1884	58
NANJING WEDO PHARMATECH CO.,LTD.	15189836218 15189836218;	wedo-chem@huawe.com	China	252	58
Hubei Rhema Reference Materials Technology Co., Ltd.	15787879035 15787875101	ydw9035@rmastandards.com	China	9988	58

---

• Revumenib Citrate
• RMA-745
• Revumenib citrate hydrate,2761046-45-9,,Pharmaceutical Chemicals
• Revemeni citrate
• 2761046-45-9